TSP Capital Management Group LLC Has $227,000 Stock Holdings in Assertio Holdings, Inc. $ASRT

TSP Capital Management Group LLC lessened its holdings in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 92.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 25,056 shares of the company’s stock after selling 291,819 shares during the period. TSP Capital Management Group LLC’s holdings in Assertio were worth $227,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Assertio during the 4th quarter worth $41,000. Virtu Financial LLC acquired a new stake in Assertio during the 3rd quarter worth $26,000. Perritt Capital Management Inc grew its holdings in Assertio by 51.6% during the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after acquiring an additional 119,281 shares during the period. GSA Capital Partners LLP grew its holdings in Assertio by 536.0% during the 3rd quarter. GSA Capital Partners LLP now owns 381,584 shares of the company’s stock worth $336,000 after acquiring an additional 321,584 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Assertio by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock worth $3,899,000 after acquiring an additional 41,332 shares during the period. Institutional investors and hedge funds own 48.96% of the company’s stock.

Assertio Price Performance

Shares of ASRT stock opened at $18.60 on Wednesday. Assertio Holdings, Inc. has a 12-month low of $7.65 and a 12-month high of $20.45. The firm has a market capitalization of $119.88 million, a price-to-earnings ratio of -3.83 and a beta of 0.43. The company has a quick ratio of 1.51, a current ratio of 1.70 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average of $13.59 and a 200-day moving average of $12.30.

Assertio (NASDAQ:ASRT) last posted its quarterly earnings data on Monday, March 16th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($3.05) by $1.19. The business had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $6.20 million. Assertio had a negative net margin of 25.59% and a negative return on equity of 30.26%. On average, equities research analysts forecast that Assertio Holdings, Inc. will post -0.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assertio in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price (up from $3.00) on shares of Assertio in a report on Monday, January 5th. Zacks Research lowered shares of Assertio from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, Wall Street Zen lowered shares of Assertio from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Assertio presently has an average rating of “Hold” and an average target price of $35.00.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.